Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.

Nephrol Dial Transplant · 2025 · PMC12394133 · PMID 40053493

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

It has been shown that treatment with the SGLT2 inhibitor dapagliflozin leads to a positive trend for heart failure but not MACE incidence [ 21 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.